Table 3.
Clinical outcomes by treatment type (N = 51 patients)
| Treatment | n | CR | SR | PR | NR | ESKD or death | aP |
|---|---|---|---|---|---|---|---|
| No immunosuppression | 17/51 (33.3%) | 0/17 (0%) | 0/17 (0%) | 1/17 (5.9%) | 16/17 (94.1%) | 8/16 with NR | N/A |
| Corticosteroids | 12/51 (23.5%) | 2/12 (16.7%) | 0/12 (0%) | 1/12 (8.3%) | 9/12 (75.0%) | 5/9 with NR | 0.28 |
| Rituximab | 3/51 (5.9%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) | 0/3 with NR | 1.00 |
| Combination | 15/51 (29.4%) | 3/15 (20%) | 3/15 (20%) | 5/15 (33.3%) | 4/15 (26.7%) | 4/4 with NR | 0.0004 untx vs. treated |
| Other | 4/51 (7.8%) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) | 2/4 with NR | 1.00 |
| Total | 51/51 (100%) | 5/51 (9.8%) | 3/51 (5.9%) | 7/51 (13.7%) | 36/51 (70.6%) | 19/36 with NR (52.8%) | 0.01 untx vs. treated |
CR, complete response/remission; ESKD, end-stage kidney disease; n, number of patients; NR, no response; PR, partial response; SR, significant response; untx, untreated.
CR: Return of normal kidney function (Cr ≤1.2).
SR: Decrease in creatinine of ≥50%.
PR: Decrease in serum creatinine of ≤50%.
NR: Failure to meet above parameters, ESKD, or death.
P-values represent contingency analysis using Fisher's exact test, comparing remission to no response.
a
P-values represent Fisher's exact tests with comparison to the no immunosuppression group.